Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Chemoimmunotherapy and Hypofractionated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.

NCT01903083 is registered in ClinicalTrials.gov with Providence Health & Services as lead sponsor.

NCT NCT01903083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01903083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Chemoimmunotherapy and Hypofractionated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Lead sponsor
Providence Health & Services
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2013
Completion date
December 31, 2017
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced malignant neoplasm